{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:32:59Z","timestamp":1790872379229,"version":"4.1.0"},"reference-count":136,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.007","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T13:26:43Z","timestamp":1710336403000},"page":"405-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Psoriasis Comorbidities and Their Treatment Impact"],"prefix":"10.1016","volume":"42","author":[{"given":"Mark","family":"Taliercio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.det.2024.02.007_bib3","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.58.4.226","article-title":"Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease","volume":"58","author":"Punzi","year":"1999","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.det.2024.02.007_bib5","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","article-title":"Sex- and gender-related differences in psoriatic arthritis","volume":"18","author":"Tarannum","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib6","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.semarthrit.2021.04.003","article-title":"Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes","volume":"51","author":"Meissner","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjd.12190","article-title":"Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)","volume":"168","author":"Coates","year":"2013","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.007_bib8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","article-title":"High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires","volume":"72","author":"Haroon","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.det.2024.02.007_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jdv.15443","article-title":"Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry","volume":"33","author":"Mease","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.det.2024.02.007_bib10","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.det.2024.02.007_bib11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.autrev.2016.03.003","article-title":"Autoantibodies in inflammatory arthritis","volume":"15","author":"Conigliaro","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"Suppl 1","key":"10.1016\/j.det.2024.02.007_bib12","first-page":"52","article-title":"Laboratory findings in psoriatic arthritis","volume":"59","author":"Punzi","year":"2007","journal-title":"Reumatismo"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med"},{"issue":"64","key":"10.1016\/j.det.2024.02.007_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.15557\/JoU.2016.0007","article-title":"Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features","volume":"16","author":"Sudo\u0142-Szopi\u0144ska","year":"2016","journal-title":"J\u00a0Ultrason"},{"issue":"65","key":"10.1016\/j.det.2024.02.007_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.15557\/JoU.2016.0018","article-title":"Diagnostic imaging of psoriatic arthritis. Part II: magnetic resonance imaging and ultrasonography","volume":"16","author":"Sudo\u0142-Szopi\u0144ska","year":"2016","journal-title":"J\u00a0Ultrason"},{"issue":"5","key":"10.1016\/j.det.2024.02.007_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054901","article-title":"Psoriatic Arthritis: Pathogenesis and Targeted Therapies","volume":"24","author":"Azuaga","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.007_bib18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/ard.2008.089367","article-title":"Familial aggregation of psoriatic arthritis","volume":"68","author":"Chandran","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-015-0640-3","article-title":"Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype","volume":"17","author":"FitzGerald","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41584-019-0364-x","article-title":"Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis","volume":"16","author":"Gracey","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib21","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1038\/s41467-018-06933-4","article-title":"Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis","volume":"9","author":"Cambr\u00e9","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.det.2024.02.007_bib22","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/acr.20496","article-title":"Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis","volume":"63","author":"Eder","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/1744666X.2019.1543591","article-title":"The relationship between smoking, psoriasis and psoriatic arthritis","volume":"15","author":"Pezzolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.det.2024.02.007_bib24","doi-asserted-by":"crossref","first-page":"101694","DOI":"10.1016\/j.berh.2021.101694","article-title":"Pathogenesis of psoriatic arthritis","volume":"35","author":"Stober","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.det.2024.02.007_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.007_bib27","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3899\/jrheum.220315","article-title":"Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations","volume":"50","author":"Leung","year":"2023","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1186\/s12916-022-02617-5","article-title":"Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.det.2024.02.007_bib30","doi-asserted-by":"crossref","first-page":"918224","DOI":"10.3389\/fimmu.2022.918224","article-title":"The Association Between Psoriasis and Risk of Cardiovascular Disease: A Mendelian Randomization Analysis","volume":"13","author":"Gao","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.det.2024.02.007_bib31","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/jid.2015.87","article-title":"Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink","volume":"135","author":"Parisi","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.02.007_bib32","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/jid.2015.218","article-title":"Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3","volume":"135","author":"Ogdie","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00403-016-1712-1","article-title":"Psoriasis and cardiovascular events: updating the evidence","volume":"309","author":"Raaby","year":"2017","journal-title":"Arch Dermatol Res"},{"issue":"14","key":"10.1016\/j.det.2024.02.007_bib34","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.det.2024.02.007_bib35","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.det.2024.02.007_bib36","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib37","first-page":"e14","article-title":"Psoriasis and cardiovascular screening rates in the United States","volume":"12","author":"Alamdari","year":"2013","journal-title":"J\u00a0Drugs Dermatol JDD"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib38","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1365-2133.2007.08190.x","article-title":"Psoriasis patients show signs of insulin resistance","volume":"157","author":"Boehncke","year":"2007","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib39","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jdv.12257","article-title":"C-reactive protein in psoriasis: a review of the literature","volume":"28","author":"Beygi","year":"2014","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib40","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.180.3.1141","article-title":"Overexpression of vascular permeability factor\/vascular endothelial growth factor and its receptors in psoriasis","volume":"180","author":"Detmar","year":"1994","journal-title":"J\u00a0Exp Med"},{"issue":"8","key":"10.1016\/j.det.2024.02.007_bib41","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1600-0625.2010.01095.x","article-title":"Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis","volume":"19","author":"Garbaraviciene","year":"2010","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.007_bib43","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.atherosclerosis.2014.11.004","article-title":"Association between psoriasis and coronary calcium score","volume":"237","author":"Staniak","year":"2014","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib44","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jaad.2021.09.069","article-title":"Epicardial adipose tissue volume is greater in men with severe psoriasis, implying an increased cardiovascular disease risk: A cross-sectional study","volume":"86","author":"Ellis","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.007_bib45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12944-016-0271-y","article-title":"Epicardial fat tissue in patients with psoriasis:a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2016","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2012.06.068","article-title":"Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis","volume":"224","author":"Mehta","year":"2012","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.det.2024.02.007_bib47","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamadermatol.2016.1984","article-title":"Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis","volume":"152","author":"Hjuler","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.02.007_bib48","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamacardio.2019.2589","article-title":"Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index","volume":"4","author":"Elnabawi","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"8","key":"10.1016\/j.det.2024.02.007_bib49","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jdv.14951","article-title":"Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis","volume":"32","author":"Wu","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"8","key":"10.1016\/j.det.2024.02.007_bib50","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.jid.2017.06.001","article-title":"Does Treatment of Psoriasis Reduce Cardiovascular Comorbidities?","volume":"137","author":"Lebwohl","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2024.02.007_bib51","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.3389\/fimmu.2019.03096","article-title":"IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications","volume":"10","author":"von Stebut","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib52","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.det.2024.02.007_bib53","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks","volume":"139","author":"von Stebut","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cjca.2019.06.021","article-title":"Effects of Interleukin 17A Inhibition on Myocardial Deformation and Vascular Function in Psoriasis","volume":"36","author":"Makavos","year":"2020","journal-title":"Can J Cardiol"},{"issue":"12","key":"10.1016\/j.det.2024.02.007_bib55","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3 Pt 1","key":"10.1016\/j.det.2024.02.007_bib56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib57","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","article-title":"Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies","volume":"68","author":"Armstrong","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib58","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjd.12473","article-title":"Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"169","author":"Coto-Segura","year":"2013","journal-title":"Br J Dermatol"},{"issue":"19","key":"10.1016\/j.det.2024.02.007_bib59","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.det.2024.02.007_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/nu15122707","article-title":"Metabolic Syndrome Screening and Nutritional Status of Patients with Psoriasis: A Scoping Review","volume":"15","author":"Mohamed Haris","year":"2023","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib61","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s00431-020-03924-w","article-title":"Metabolic syndrome and insulin resistance in pre-pubertal children with psoriasis","volume":"180","author":"Caroppo","year":"2021","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.det.2024.02.007_bib62","doi-asserted-by":"crossref","first-page":"711060","DOI":"10.3389\/fimmu.2021.711060","article-title":"Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions","volume":"12","author":"Hao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.det.2024.02.007_bib63","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biopha.2018.02.103","article-title":"The potential pathogenic role of IL-17\/Th17 cells in both type 1 and type 2 diabetes mellitus","volume":"101","author":"Abdel-Moneim","year":"2018","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib64","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.02.007_bib65","first-page":"5076858","article-title":"Elevated Serum TNF-\u03b1 Is Related to Obesity in Type 2 Diabetes Mellitus and Is Associated with Glycemic Control and Insulin Resistance","volume":"2020","author":"Alzamil","year":"2020","journal-title":"J\u00a0Obes"},{"key":"10.1016\/j.det.2024.02.007_bib66","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cyto.2016.06.028","article-title":"Adiponectin, TNF-\u03b1 and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis","volume":"86","author":"Liu","year":"2016","journal-title":"Cytokine"},{"issue":"11","key":"10.1016\/j.det.2024.02.007_bib67","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/ijd.13699","article-title":"Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction","volume":"56","author":"Lynch","year":"2017","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030859","article-title":"The Roles of Lipoprotein in Psoriasis","volume":"21","author":"Shih","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.det.2024.02.007_bib69","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1007\/s13555-022-00790-2","article-title":"Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review","volume":"12","author":"Merola","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib70","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjd.16008","article-title":"Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"178","author":"Gordon","year":"2018","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.det.2024.02.007_bib71","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","article-title":"Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis","volume":"31","author":"Pinter","year":"2020","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.det.2024.02.007_bib72","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jaad.2019.09.042","article-title":"Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: Post hoc analysis of 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)","volume":"82","author":"Lebwohl","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib73","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/bjd.20971","article-title":"Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial","volume":"186","author":"Augustin","year":"2022","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib74","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1468-3083.2007.02429.x","article-title":"Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study","volume":"22","author":"Gisondi","year":"2008","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib75","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1210\/jc.2010-1170","article-title":"TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome","volume":"96","author":"Stanley","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib76","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.02.007_bib77","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.02.007_bib78","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","article-title":"Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women","volume":"72","author":"Li","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.det.2024.02.007_bib79","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2340\/00015555-0770","article-title":"Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany","volume":"90","author":"Augustin","year":"2010","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2024.02.007_bib80","unstructured":"CDC. What is Inflammatory Bowel Disease? 2022."},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib81","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s13555-023-00904-4","article-title":"Paradoxical Reactions to Anti-TNF\u03b1 and Anti-IL-17 Treatment in Psoriasis Patients: Are Skin and\/or Gut Microbiota Involved?","volume":"13","author":"Jiraskova Zakostelska","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib82","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1159\/000500116","article-title":"Psoriasis and Inflammatory Bowel Disease","volume":"37","author":"Cottone","year":"2019","journal-title":"Dig Dis"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib83","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib84","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2020.05.008","article-title":"The current landscape of psoriasis genetics in 2020","volume":"99","author":"Ogawa","year":"2020","journal-title":"J\u00a0Dermatol Sci"},{"issue":"5804","key":"10.1016\/j.det.2024.02.007_bib85","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A\u00a0genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.det.2024.02.007_bib86","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jaad.2017.06.043","article-title":"Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation","volume":"78","author":"Whitlock","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib87","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"23","key":"10.1016\/j.det.2024.02.007_bib88","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2024.02.007_bib89","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1007\/s10620-023-08062-5","article-title":"An Assessment of Comparative Medication Durability in Inflammatory Bowel Disease Patients With and Without Co-morbid Psoriasis, Rheumatoid Arthritis, and\/or Enteropathic Arthritis","volume":"68","author":"Cushing","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.det.2024.02.007_bib90","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.det.2024.02.007_bib91","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.det.2024.02.007_bib92","doi-asserted-by":"crossref","first-page":"847160","DOI":"10.3389\/fimmu.2022.847160","article-title":"Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis","volume":"13","author":"Xie","year":"2022","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.det.2024.02.007_bib93","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.det.2024.02.007_bib94","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.det.2024.02.007_bib95","doi-asserted-by":"crossref","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: A study based on literature and database analysis","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.det.2024.02.007_bib96","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40265-023-01882-9","article-title":"Targeting IL-23 for IBD: Rationale and Progress to Date","volume":"83","author":"Vuyyuru","year":"2023","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib97","first-page":"438","article-title":"Management of Concomitant Inflammatory Bowel Disease or Uveitis in Patients with Psoriatic Arthritis: An Updated Review Informing the 2021 GRAPPA Treatment Recommendations","volume":"50","author":"Jadon","year":"2023","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.det.2024.02.007_bib98","doi-asserted-by":"crossref","first-page":"9308341","DOI":"10.1155\/2020\/9308341","article-title":"Psoriasis and Risk of Uveitis: A Systematic Review and Meta-Analysis","volume":"2020","author":"Chaiyabutr","year":"2020","journal-title":"BioMed Res Int"},{"issue":"7","key":"10.1016\/j.det.2024.02.007_bib99","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdv.19060","article-title":"Risk of uveitis in patients with psoriasis in Korea: A nationwide population-based cohort study","volume":"37","author":"Kim","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.det.2024.02.007_bib100","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/1346-8138.16062","article-title":"Risk of retinal diseases in patients with psoriasis: A population-based cohort study in Taiwan","volume":"48","author":"Dai","year":"2021","journal-title":"J\u00a0Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.02.007_bib101","doi-asserted-by":"crossref","first-page":"e0201285","DOI":"10.1371\/journal.pone.0201285","article-title":"Increased risk of keratopathy after psoriasis: A nationwide population-based study","volume":"13","author":"Lee","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.det.2024.02.007_bib102","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jfo.2019.03.038","article-title":"[Uveitis: Diagnosis and work-up]","volume":"43","author":"Bonnet","year":"2020","journal-title":"J\u00a0Fr Ophtalmol"},{"issue":"7","key":"10.1016\/j.det.2024.02.007_bib103","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s10792-022-02225-5","article-title":"Psoriasis and uveitis","volume":"42","author":"K\u00f6se","year":"2022","journal-title":"Int Ophthalmol"},{"issue":"5","key":"10.1016\/j.det.2024.02.007_bib104","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1001\/jamaophthalmol.2017.0569","article-title":"Risk of Uveitis Among People With Psoriasis: A Nationwide Cohort Study","volume":"135","author":"Chi","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.det.2024.02.007_bib105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib106","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3109\/08820538.2016.1170161","article-title":"Psoriasis and Psoriatic Arthritis-Related Uveitis: Different Ophthalmological Manifestations and Ocular Inflammation Features","volume":"32","author":"Abbouda","year":"2017","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"10.1016\/j.det.2024.02.007_bib107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.01.014","article-title":"Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis","volume":"139","author":"El-Asrar","year":"2011","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib108","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3109\/09273948.2013.815786","article-title":"Elevated serum levels of interleukin-17A in uveitis patients","volume":"21","author":"Jawad","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"10.1016\/j.det.2024.02.007_bib109","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/bjo.2009.169052","article-title":"Elevated serum IL-23 correlates with intraocular inflammation after cataract surgery in patients with Vogt-Koyanagi-Harada disease","volume":"94","author":"Jiang","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.det.2024.02.007_bib110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00417-003-0706-9","article-title":"Association between HLA-A2 in Japanese psoriasis arthritis and susceptibility to uveitis","volume":"241","author":"Keino","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib111","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1590\/S0365-05962012000600009","article-title":"Psoriasis and uveitis: a literature review","volume":"87","author":"Fraga","year":"2012","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib112","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nri3459","article-title":"Immunology of age-related macular degeneration","volume":"13","author":"Ambati","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"7\u20138","key":"10.1016\/j.det.2024.02.007_bib113","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1080\/09273948.2020.1749857","article-title":"Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation","volume":"29","author":"Liberman","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib114","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/09273948.2015.1134581","article-title":"Adalimumab for Ocular Inflammation","volume":"25","author":"Durrani","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13075-023-03127-2","article-title":"Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort","volume":"25","author":"Reich","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib116","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.mjafi.2020.10.014","article-title":"Anxiety, depression and harmful use of alcohol in severe chronic plaque psoriasis: A cross-sectional study","volume":"79","author":"Mathur","year":"2023","journal-title":"Med J Armed Forces India"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib117","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2340\/00015555-3145","article-title":"Epidemiology of Depression in Patients with Psoriasis: A Nationwide Population-based Cross-sectional Study","volume":"99","author":"Hu","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2024.02.007_bib118","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2023.05.059","article-title":"Evidence for a causal association between psoriasis and psychiatric disorders using a bidirectional Mendelian randomization analysis in up to 902,341 individuals","volume":"337","author":"Wang","year":"2023","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.det.2024.02.007_bib119","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.genhosppsych.2022.01.006","article-title":"Associations between psoriasis and mental illness: an update for clinicians","volume":"75","author":"Hedemann","year":"2022","journal-title":"Gen Hosp Psychiatr"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib120","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/jid.2013.508","article-title":"The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis","volume":"134","author":"Dowlatshahi","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib121","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/jid.2014.530","article-title":"The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries","volume":"135","author":"Dalgard","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib122","first-page":"177","article-title":"Pro-inflammatory Cytokines, Biomarkers, Genetics and the Immune System: A Mechanistic Approach of Depression and Psoriasis","volume":"47","author":"Aleem","year":"2018","journal-title":"Rev Colomb Psiquiatr (Engl Ed)"},{"issue":"12","key":"10.1016\/j.det.2024.02.007_bib123","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/jdv.14460","article-title":"Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression","volume":"31","author":"Koo","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2024.02.007_bib124","first-page":"99","article-title":"Biologics Can Significantly Improve Dermatology Life Quality Index (DLQI) in Psoriatic Patients: A Systematic Review","volume":"12","author":"de Ruiter","year":"2022","journal-title":"Psoriasis (Auckl)"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib125","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/ijd.ijd_241_22","article-title":"The Effects of Methotrexate and Biologics on the Symptoms of Depression and Anxiety in Patients with Psoriasis","volume":"68","author":"U\u011furer","year":"2023","journal-title":"Indian J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.02.007_bib126","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jamadermatol.2020.1054","article-title":"Association Between the Mental Health of Patients With Psoriasis and Their Satisfaction With Physicians","volume":"156","author":"Read","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.02.007_bib127","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/jdv.15012","article-title":"Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study","volume":"32","author":"Gordon","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2024.02.007_bib128","first-page":"1","article-title":"Brodalumab: A Review of Safety","volume":"23","author":"Rusta-Sallehy","year":"2018","journal-title":"Skin Therapy Lett"},{"issue":"12","key":"10.1016\/j.det.2024.02.007_bib129","first-page":"44","article-title":"The Use of Brodalumab in Three Patients with Psoriasis and Psychiatric Comorbidities","volume":"13","author":"Rivera-Oyola","year":"2020","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.02.007_bib130","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archderm.139.11.1425","article-title":"Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom","volume":"139","author":"Gelfand","year":"2003","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.007_bib131","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The Risk of Cancer in Patients With Psoriasis: A Population-Based Cohort Study in the Health Improvement Network","volume":"152","author":"Chiesa Fuxench","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.02.007_bib132","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"issue":"6","key":"10.1016\/j.det.2024.02.007_bib133","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaad.2008.12.031","article-title":"Treatments for psoriasis and the risk of malignancy","volume":"60","author":"Patel","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.007_bib134","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.007_bib135","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The Epidemiology of Psoriatic Arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"issue":"7","key":"10.1016\/j.det.2024.02.007_bib136","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamadermatol.2017.0499","article-title":"Pediatric Psoriasis Comorbidity Screening Guidelines","volume":"153","author":"Osier","year":"2017","journal-title":"JAMA Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T06:50:49Z","timestamp":1731567049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":136,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0733863524000196"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.007","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriasis Comorbidities and Their Treatment Impact","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}